ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

Core Viewpoint - ANI Pharmaceuticals, Inc. has launched Nitazoxanide Tablets, a generic version of Alinia®, highlighting its commitment to providing affordable, high-quality medicines [1][2]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics, with a mission of "Serving Patients, Improving Lives" [3]. - The company aims for sustainable growth through its Rare Disease business, Generics business, and Brands business [3]. Product Launch Details - The newly launched Nitazoxanide Tablets are 500 mg and represent a niche product with limited competition [1]. - U.S. annual sales for Nitazoxanide Tablets are approximately $36.1 million, based on December 2024 moving annual total (MAT) IQVIA data [2]. Partnership Information - ANI Pharmaceuticals has partnered with Biophore India Pharmaceuticals Pvt. Ltd. for the launch of Nitazoxanide Tablets, emphasizing a shared commitment to affordable medicines [2][4].